Introduction
============

Osteoporosis is the most common bone metabolic disease that is characterized by decreased bone mass and structural deterioration of bone tissue, leading to an increased risk of bone fracture at the different skeletal sites such as spine, hip and wrist [@B1]. The incidence of osteoporosis is closely related to aging in both women and men, which is associated with oxidative stress [@B2]. Recently, much attention has been paid to the adverse effects of oxidative stress on bone formation [@B3], [@B4]. Oxidative stress shifts a balance in bone remodeling toward increased bone resorption by osteoclasts and decreased bone formation by osteoblasts, which can eventually result in accelerated osteoporosis [@B5]. Oxidative stress has been shown to inhibit osteogenic potential of MSCs and promotes apoptosis of mature osteoblasts [@B6], [@B7]. Furthermore, several studies showed that oxidative stress could interfere with multiple cellular events that induced MSC differentiation, including Wnt/beta-catenin and FOXO signaling pathways [@B8]-[@B10].

Human MSCs are multipotent adult progenitor cells that have a capacity for self-renewal and can differentiate into specialized cell types such as osteocytes, adipocytes and chondrocytes [@B11]. MSCs have been easily isolated and expanded without severe functional damages from various sources, including bone marrow, adipose tissue, umbilical cord blood and Wharton\'s jelly which harbor a stem cell population [@B12]. MSCs that manifested the immunomodulatory properties produced several cytokines and growth factors in order to create supportive microenvironment for themselves in host tissue [@B13]. Moreover, several studies have demonstrated that MSCs can be used as ideal candidates for tissue regeneration due to their capability to replace damaged tissue at sites of injury *in vivo* [@B14].

Melatonin, *N*-acetyl-5-methoxytryptamine, is a tryptophan-derived hormone secreted by the pineal gland in the brain. Melatonin has drawn considerable therapeutic interest for various disorders as a consequence of its multiple biological functions including control of circadian rhythms, tumor inhibition, antioxidant activity, and immunomodulatory properties [@B15]. Recently, melatonin has been demonstrated to exert protective effects against ischemia/reperfusion injury *in vitro* and *in vivo* via inhibition of oxidative stress, inflammation and apoptosis, supporting that melatonin has antioxidant properties with strong cytoprotective activities [@B16]-[@B18].

Melatonin has also an influence on skeleton formation and development through regulating the balance between bone resorption by osteoclasts and bone formation by osteoblasts. Melatonin at pharmacological concentrations suppressed the osteoclast differentiation of mouse bone marrow-derived monocytes in a dose-dependent manner via attenuation of intracellular ROS and inhibition of the NF-κB signaling pathway [@B19], [@B20]. Treatment with high doses of melatonin (up to 50 mg/kg) caused an inhibition of bone resorption and an increase in bone mass in mice [@B21]. In contrast to the inhibitory effect of melatonin on bone resorption by osteoclast, stimulatory effects of melatonin on bone formation have been reported previously [@B22]-[@B24]. Melatonin has also been shown to play an important role in directing the differentiation of MSCs towards specific lineages [@B25], [@B26]. Taken together, these results suggest that melatonin shifts bone remodeling toward bone formation over bone resorption by osteoclasts. However, the mechanism for melatonin to promote osteogenic differentiation of MSCs has not been fully understood. Furthermore, whether antioxidant activity of melatonin can also restore osteogenic potential of MSC inhibited by oxidative stress and its protective mechanism against the oxidative stress remains to be determined.

AMP-activated protein kinase (AMPK), a highly conserved serine/threonine kinase, exists as a heterotrimeric complex of a catalytic α subunit and two regulatory β and γ subunits [@B27]. AMPK plays a critical role as a metabolic sensor in maintaining both cellular and whole-body energy homeostasis by modulating glucose and lipid metabolism, as well as by facilitating appropriate adaptive responses to ATP-consuming conditions such as ischemia/reperfusion, hypoxia, oxidative stress, and exercise [@B28]. Moreover, AMPK has emerged as a potential therapeutic target for the treatments of a variety of diseases, including obesity, type 2 diabetes, cardiovascular diseases, and other metabolic diseases [@B29], [@B30]. Indeed, it has been documented that pharmacological activation of AMPK has been shown to provide cardioprotection against myocardial ischemia/reperfusion injury in animal models of type 2 diabetes [@B31], [@B32]. Recent studies have also shown that AMPK activation could positively regulates bone homeostasis through enhancement of the osteogenic potential of MSCs [@B33]-[@B37]. However, there are no studies examining whether AMPK activation is involved in the effect of melatonin on the osteogenic potential of MSCs.

In the present study, considering the relevance of oxidative stress as a risk factor in the development of osteoporosis, we investigated the effect of melatonin on osteogenic differentiation *per se* and oxidative stress-inhibited osteogenic differentiation of human MSCs and the underlying mechanisms. We demonstrated that melatonin enhanced osteogenic potential of MSCs and effectively antagonized the deleterious effects of oxidative stress on osteoblast differentiation of the MSCs through AMPK activation.

Materials and methods
=====================

Reagents and antibodies
-----------------------

The cell culture plates and flasks were purchased from SPL Life Sciences (Pocheon, South Korea). α-Minimum essential medium (α-MEM) was purchased from Gibco (Grand Island, NY, USA). Antibiotics (10,000 units/mL penicillin and 10,000 μg/mL streptomycin) were purchased from Hyclone (Logan, UT, USA). Fetal bovine serum (FBS) was purchased from Welgene (Daegu, South Korea). Compound C was purchased from Calbiochem (Darmstadt, Germany). Protease inhibitor cocktail tablets were purchased from Thermo Fisher Scientific (Waltham, MA, USA). The primary antibodies against phospho-AMPKα (Thr172) and RUNX2 were purchased from Cell Signaling Technology (Danvers, MA, USA), and antibodies against AMPKα1/2, FOXO3a, and β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Invitrogen (Carlsbad, CA, USA). All other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified.

Cell culture
------------

Human bone marrow-derived MSCs were purchased from ScienCell Research Laboratories (Cat. No. 7500; Carlsbad, CA, USA) and maintained in a growth medium consisting of α-MEM supplemented with 16.5% FBS and antibiotics (100 units/mL penicillin and 100 μg/mL streptomycin) at 37°C in a humidified atmosphere of 5% CO~2~ and 95% air. Cells between passages 3 and 10 were used for all experiments.

Cell viability assay
--------------------

Cell viability was assessed by the methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay. Briefly, cells were seeded in 96-well microplates at 8 × 10^3^ cells/well and incubated at specified conditions for an indicated time period. Medium was aspirated and then cells were incubated with 100 μl MTT solution (5 mg/ml MTT in PBS) for 4 h. After the MTT formazan crystals were dissolved in 100 μl of lysis buffer containing 10% SDS in 0.01N HCl, the absorbance was measured at 570 nm using a Multiskan^TM^ GO microplate reader (Thermo Fisher Scientific).

Osteoblast differentiation and H~2~O~2~ treatment
-------------------------------------------------

For osteogenic differentiation, human MSCs were plated at density of 3 × 10^5^ cells/well in 6-well plates or 1 × 10^4^ cells/well in 96-well plates and incubated in growth medium until confluent. At that point, the growth medium was replaced with osteogenic differentiation medium (ODM) consisting of α-MEM supplemented with 10% FBS, 100 nM dexamethasone, 10 mM β-glycerophosphate, 50 μM ascorbic-2-phosphate, 100 units/mL penicillin and 100 μg/mL streptomycin. Fresh ODM was replenished twice per week. For the rescue experiment, human MSCs were pre-exposed to 100 μM H~2~O~2~ (diluted in growth medium) for 2 h. The cells were washed twice with fresh growth medium and followed by incubation in ODM with or without indicated concentrations of melatonin.

Alkaline phosphatase (ALP) activity assay
-----------------------------------------

ALP activity as an early marker of osteogenic differentiation was assessed at day 4. Cells were washed twice with PBS and then lysed with protein lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1% NP-40). ALP activity was determined colorimetrically by incubating the protein lysates with substrate *p*-nitrophenyl phosphate in 96-well plates at 37°C for 30 min. The absorbance was measured at 405 nm and normalized against the corresponding protein amounts. The values were expressed as fold change relative to undifferentiated cells.

Alizarin Red S staining
-----------------------

Osteogenic differentiation of human MSCs was assessed by Alizarin Red S staining for the presence of calcium deposits. Briefly, the cells were washed twice with PBS, fixed with 4% formaldehyde for 30 min at room temperature, rinsed with distilled water, and then stained with 2% (w/v) Alizarin Red S dissolved in distilled water (pH 4.2; adjusted with 10% ammonium hydroxide) for 20 min. Cells were then washed extensively with distilled water and examined for mineralization. After imaging, the dye was eluted with 10% (w/v) cetylpyridinium chloride monohydrate in 10 mM sodium phosphate (pH 7.0) for 1 h at room temperature, and the absorbance was measured at 570 nm using a Multiskan^TM^ GO microplate reader (Thermo Fisher Scientific).

Western blot analysis
---------------------

Cells were washed twice with PBS and lysed in RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 5 mM sodium fluoride, 2 mM sodium orthovanadate, 1 mM PMSF, and protease inhibitor cocktail). Protein concentrations in the supernatant were determined using a BCA protein assay kit (Thermo Fisher Scientific). Equal amounts of total protein (25 μg) were separated on 10% SDS-PAGE and transferred onto Hybond-ECL nitrocellulose membranes (Amersham, Arlington Heights, IL, USA). The membranes were blocked with Tris-buffered saline-Tween 20 (TBS-T: 10 mM Tris-HCl pH 7.6, 150 mM NaCl, and 0.1% Tween 20) containing 5% nonfat dry milk and incubated with primary antibodies diluted in blocking buffer overnight at 4°C. The membranes were washed three times with TBS-T and then incubated with appropriate HRP-conjugated secondary antibodies for 1 h at room temperature. The blots were visualized using ECL detection reagents (Advansta, Menlo Park, CA, USA).

Statistical analysis
--------------------

All data were expressed as the mean ± standard error of the mean (SEM). Differences between groups were examined for statistical significance using Student\'s *t*-test. The difference was considered to be significant if *P* \< 0.05.

Results
=======

Effects of melatonin on cell viability
--------------------------------------

Cell viability of human MSCs treated with 1, 10, 100, and 1,000 μM melatonin was determined using the MTT assay (Fig. [1](#F1){ref-type="fig"}A and B). There was no toxicity at the concentrations of 1, 10, and 100 μM, but the cell viability was decreased by toxicity at the concentration of 1,000 μM, regardless of the type of medium used (basal or osteogenic), suggesting a dose-dependent effect of melatonin on the viability of human MSCs. Therefore, the subsequent experiments were carried out at concentrations of 1, 10, and 100 μM.

Melatonin stimulates osteoblast differentiation of human MSCs
-------------------------------------------------------------

We next investigated the effects of melatonin on both early and late stages of osteoblast differentiation process. Human MSCs were treated with ODM and melatonin at different doses during the first 4 days. ALP activity assay was performed to assess the effect of melatonin on the early stage of osteoblast differentiation (Fig. [2](#F2){ref-type="fig"}A). ALP activity was higher in the osteogenic medium-treated group compared with the control group, and was significantly increased further by treatment with melatonin in a dose-dependent manner. Interestingly, melatonin alone also promotes osteoblast differentiation of human MSCs in a dose-dependent manner, as judged by increasing their ALP activity. The degree of calcium deposition was also detected by Alizarin Red S staining (Fig. [2](#F2){ref-type="fig"}B and C). When melatonin (100 μM) was treated for 14 days, the degree of calcium deposition was markedly increased when compared with human MSCs treated with ODM alone. These results indicate that melatonin can exert a synergistic effect on osteoblast differentiation and may be used as a pro-osteogenic agent in stem cell based-therapy.

Melatonin significantly enhances AMPK activation during osteoblast differentiation of human MSCs
------------------------------------------------------------------------------------------------

To confirm whether the melatonin promotes osteoblast differentiation through AMPK activation, human MSCs were treated with vehicle or indicated concentrations of melatonin for 24 h with ODM. AMPK phosphorylation and the expression levels of its downstream effectors, FOXO3a and RUNX2 that were closely associated with the osteoblast differentiation, were detected by Western blot analysis. Interestingly, the activating phosphorylation of AMPK and the protein expression of FOXO3a and RUNX2 were significantly increased by melatonin in a dose-dependent manner (Fig. [3](#F3){ref-type="fig"}A), which were suppressed by co-treatment of compound C, a synthetic AMPK inhibitor (Fig. [3](#F3){ref-type="fig"}B). These findings indicate that AMPK activation is responsible for enhanced osteoblast differentiation of human MSCs by melatonin.

Melatonin restores oxidative stress-inhibited osteoblast differentiation of human MSCs by activating AMPK
---------------------------------------------------------------------------------------------------------

Since AMPK activation has been reported to protect cells from oxidative stress [@B38], [@B39], we tested the effect of AMPK activation by melatonin on oxidative stress-inhibited osteoblast differentiation. Human MSCs were pretreated with 100 μM H~2~O~2~ for 2 h, which has no detectable adverse effect on cell viability [@B40], and then immediately treated with ODM. After 21 days of incubation was completed, AMPK activation and osteoblast differentiation were detected by Western blot analysis and Alizarin Red S staining, respectively. As shown in Fig. [4](#F4){ref-type="fig"}, H~2~O~2~ treatment markedly reduced not only the osteogenic potential of human MSCs, but also AMPK activation and protein expression of its downstream effectors, FOXO3a and RUNX2. However, these effects were reversed by melatonin treatment in a dose-dependent manner. Taken together, our findings indicate that AMPK plays an important role in the regulation of pro-osteogenic signals in human MSCs and that melatonin alleviates the oxidative stress-induced inhibition of osteoblast differentiation of human MSCs through AMPK activation.

Discussion
==========

Osteoporosis is a major public health problem throughout the world [@B1], [@B2]. Accumulating studies indicate that oxidative stress is responsible for age-related bone loss and might play an important role in development of osteoporosis in both men and women [@B3], [@B5]. Not only could oxidative stress influence osteoblast proliferation and survival, but also has a direct impact on its differentiation [@B6]. In the present study, we demonstrated that melatonin, widely known as an antioxidant, showed significant protective potential against oxidative stress-induced inhibition of osteoblast differentiation in human MSCs.

Age-related skeletal changes, including decreased osteoblast number as well as decreased bone mass and strength, are closely associated with increased oxidative stress [@B4]. Additionally, oxidative stress-induced premature cellular senescence was found to impair osteogenic differentiation potential of human and mouse MSCs [@B41], [@B42]. Consistent with previous reports [@B43], we found that oxidative stress induced the reduction in cellular ALP activity and subsequently diminished calcium deposition in parallel with a significant decrease in both FOXO3a (the key transcription factor regulating oxidative stress-induced cellular response) and RUNX2 (the key transcriptional factor initiating osteogenesis) protein levels during human MSC osteogenesis (Fig. [4](#F4){ref-type="fig"}), suggesting that oxidative stress, at least in part, could contribute to the dysfunction of tissue-specific stem/progenitor cells and that targeting oxidative stress may improve multi-lineage differentiation potential and clinical utilities of MSCs.

Osteoblast differentiation from MSCs is a well-orchestrated process and regulated by multiple signaling pathways [@B44], [@B45]. Among them is AMPK which has been emerged as a master regulator of whole-body energy homeostasis by coordinating various aspects of metabolism, such as food intake, energy expenditure, insulin secretion, hepatic glucose production, and glucose/fatty acid metabolism in skeletal muscle and adipose tissue [@B27], [@B28]. Therefore, functional disturbances of AMPK could have been linked with a wide range of cellular malfunctions and diseases [@B30]. Regarding the importance of AMPK signaling pathway in bone metabolism, it has recently been reported that AMPK regulates bone formation and bone mass both *in vitro* and *in vivo* [@B46]-[@B48]. In addition, AMPK plays an essential role in directing human MSC differentiation and fate specification [@B34], [@B49], [@B50]. Several studies have also demonstrated the protective effect of AMPK against oxidative stress in different cell types [@B38], [@B51]-[@B53]. In this study, we found that treatment of melatonin at 100 μM by itself could enhance osteogenic potential of human MSCs by activation of AMPK (Fig. [2](#F2){ref-type="fig"}). Furthermore, we demonstrated that AMPK activation by melatonin was accompanied with the increased protein expression levels of FOXO3a and RUNX2 (Fig. [3](#F3){ref-type="fig"}) as markers of oxidative stress/antioxidant defense and osteogenic potential, respectively. Therefore, activation of AMPK by melatonin is of critical importance not only in stimulation of the osteogenic potential of human MSCs, but also in protection of the potential against oxidative stress. AMPK activation is capable of eliciting the crosstalk between oxidative damage and bone formation.

FOXO proteins, characterized by a common winged-helix DNA binding domain called the forkhead box, are an evolutionarily conserved subfamily of transcription factors which play critical roles in a wide variety of biological processes including tumor suppression, regulation of energy metabolism and development in several tissues [@B54]. FOXO proteins are mainly regulated by phosphorylation-dependent nuclear-cytoplasmic shuttling [@B55]. From the viewpoint of their significance in bone formation [@B9], [@B10], [@B56], [@B57], FOXO-dependent defense mechanism against oxidative damage provides an implement for cellular adaptation to cope with oxidative free radicals generated as normal byproducts of aerobic metabolism of osteoblasts and is thereby essential for maintaining the bone mass homeostasis. FOXO3a, one of the four mammalian FOXO family members (FOXO1, FOXO3, FOXO4 and FOXO6), also promotes osteogenesis by stimulating RUNX2 gene expression which is a key transcription factor functionally related to the lineage determination and differentiation of MSCs [@B58]. Moreover, AMPK is required to directly or indirectly mediate the FOXO3a transcriptional activity in oxidative stress response [@B59]-[@B62]. We found that melatonin promotes osteogenesis in human MSCs by activating the AMPK signaling pathway, which is accompanied by increased FOXO3a and RUNX2 protein levels. In addition, melatonin alleviates oxidative stress-inhibited osteogenesis of human MSCs by activating AMPK and subsequently up-regulating of FOXO3a and RUNX2 protein levels. Taken together, these results can constitute a mechanism in which activation of AMPK by melatonin mediates upregulation of FOXO3a and RUNX2, which, in turn, stimulates osteogenic potential of human MSCs *per se* or alleviates oxidative stress-induced inhibition of the potential (Fig. [5](#F5){ref-type="fig"}). It is worth noticing that melatonin inhibits bone resorption by osteoclast through its antioxidant capacity [@B20]. Therefore, these results may provide new insights for the development of novel therapeutic strategies for combating bone metabolic diseases like osteoporosis.

Conclusion
==========

In this work, we demonstrate that melatonin stimulates the osteogenesis of human MSCs by activating the AMPK pathway. We also found that melatonin enhanced the restoration of oxidative stress-impaired osteogenesis of human MSCs in a dose-dependent manner *in vitro*. The molecular mechanism by which melatonin exerts the protective effect on human MSCs against oxidative stress is at least in part associated with an increased levels of endogenous FOXO3a and RUNX2 proteins through the activation of AMPK pathway. Our work suggests that activation of AMPK signaling by melatonin supplements may represent a new therapeutic strategy for treating metabolic bone diseases.
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![**Effects of melatonin on cell viability.** (A) Chemical structure of melatonin (from National Center of Biotechnology Information, PubChem CID: 896). (B) Human MSCs were seeded in 96-well plates at a density of 8 × 10^3^ cells/well and then treated with or without ODM containing indicated concentrations of melatonin for 3 days. Cell viability was determined using the MTT assay. Data are represented as mean ± SEM of three individual experiments (*n* = 3). Statistical significance was determined using Student\'s *t*-test (^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; compared with untreated control).](ijmsv15p1083g001){#F1}

![**Melatonin stimulates osteoblast differentiation in human MSCs.** (A) Human MSCs were seeded in 96-well plates at a density of 8 × 10^3^ cells/well and then treated with or without ODM containing indicated concentrations of melatonin for first 4 days. (B) The cells were treated with or without ODM containing indicated concentrations of melatonin for 14 days, followed by Alizarin Red S staining and visualized by phase-contrast microscopy at a final magnification of 200X. (C) The mineralized layers were dissolved and quantified using a microplate reader at 570 nm. Data are represented as mean ± SEM of three individual experiments (*n* = 3). Statistical significance was determined using Student\'s *t*-test (^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; compared with untreated control).](ijmsv15p1083g002){#F2}

![**Melatonin significantly enhances AMPK activation during osteoblast differentiation of human MSCs.** (A) Human MSCs were treated with the indicated concentrations of melatonin for 24 h under ODM. (B) Cell were treated with the indicated concentrations of melatonin (100 μM) and compound C for 24 h under ODM. Western blot analysis was performed with the specified antibodies as described in Materials and Methods. Representative data from multiple experiments are shown.](ijmsv15p1083g003){#F3}

![**Melatonin restores oxidative stress-inhibited osteoblast differentiation of human MSCs by activating AMPK signaling.** (A) Human MSCs were treated with 100 μM H~2~O~2~ and incubated in ODM with the indicated concentrations of melatonin for 21 days. The calcium deposition of human MSCs was assessed by Alizarin Red S staining. (B) The mineralized layers were dissolved and quantified using a microplate reader at 570 nm. (C) Total proteins were subjected to Western blot analysis using the specified antibodies. Data are represented as mean ± SEM of three individual experiments (*n* = 3). Statistical significance was determined using Student\'s *t*-test (^\*^*p* \< 0.05 and ^\*\*^*p* \< 0.01 in contrast to the group treated with H~2~O~2~ alone).](ijmsv15p1083g004){#F4}

![**A scheme showing the mechanism by which melatonin protects human MSCs against oxidative stress-inhibited osteogenesis.** Oxidative stress inhibits osteoblast differentiation of human MSCs by decreasing AMPK signaling. However, melatonin supplement alleviates oxidative stress-inhibited osteogenesis by restoring the *in vitro* differentiation potential of human MSCs through activation of AMPK-FOXO3a-RUNX2 axis. The proposed scheme suggests a therapeutic potential of melatonin in MSC-based bone regeneration and repair.](ijmsv15p1083g005){#F5}
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